{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:33Z","timestamp":1792036893469,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-062"],"award-info":[{"award-number":["2022-PUMCH-B-062"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2023-PUMCH-F-004"],"award-info":[{"award-number":["2023-PUMCH-F-004"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-053"],"award-info":[{"award-number":["2021-I2M-1-053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti\u2013PD-1\/PD-L1 inhibitors. By assessing PD-L1 expression, we sought to determine the potential therapeutic benefit of PD-1\/PD-L1 inhibitors in OCCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>The retrospective study included 152 individuals with OCCC between 2019 and 2022 at Peking Union Medical College Hospital. Paired tumors of primary versus recurrent lesions (17 pairs from 15 patients) or primary versus metastatic lesions (11 pairs from 9 patients) were also included. The 22C3 pharmDx assay and whole sections were used for PD-L1 immunohistochemical staining. Pathologists with experience in premarket clinical trials evaluated PD-L1 expression based on various diagnostic criteria (TPS 1%, CPS 1, or CPS 10). The number and percentage of positive PD-L1 cases were 34 (22.4%, TPS\u2009\u2265\u20091%) and 59 (38.8%, CPS\u2009\u2265\u20091), respectively. Thirty-three (21.7%) of the cases had high PD-L1 expression (CPS\u2009\u2265\u200910). Half of the platinum-resistant patients (11\/22) were PD-L1 positive (CPS\u2009\u2265\u20091). In addition, positive PD-L1 expression (CPS\u2009\u2265\u20091) was related to clinicopathological characteristics that represented a worse prognosis, such as advanced stages, lymph node metastasis, and distant metastasis (<jats:italic>p<\/jats:italic>\u2009=\u20090.032, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.003, separately). PD-L1 was expressed equally or more in the recurrent lesion compared with its matched primary lesion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, anti\u2013PD-1\/PD-L1 inhibitors are a promising therapeutic choice for OCCC. For evaluation of PD-L1 expression, CPS is more recommended than TPS. Evaluation of recurrent lesion was still suitable and predictive when the primary tumor tissue was not available. Distant metastatic lesions can serve as alternative samples for PD-L1 evaluation, while usage of lymphatic metastatic lesions is not recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-024-01510-4","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:01:35Z","timestamp":1718449295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay"],"prefix":"10.1186","volume":"19","author":[{"given":"Yike","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boju","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"1","key":"1510_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1510_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109(3):370\u20136.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1510_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"1510_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1055\/a-1475-4335","volume":"81","author":"H Bronger","year":"2021","unstructured":"Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - current aspects. Geburtshilfe Frauenheilkd. 2021;81(10):1128\u201344.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"5","key":"1510_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111\u201322.","journal-title":"Hum Vaccin Immunother"},{"key":"1510_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1510_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1510_CR8","unstructured":"Administration UFaD. Companion diagnostic devices for a specific group of oncology therapeutic products\u2014guidance for industry 2020 [ https:\/\/www.fda.gov\/media\/120340\/download"},{"key":"1510_CR9","doi-asserted-by":"crossref","unstructured":"Maule JG, Clinton LK, Graf RP, Xiao J, Oxnard GR, Ross JS et al. Comparison of PD-L1 tumor cell expression with 22C3, 28\u2009\u2013\u20098, and SP142 IHC assays across multiple tumor types. J Immunother Cancer. 2022;10(10).","DOI":"10.1136\/jitc-2022-005573"},{"issue":"16","key":"1510_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973\u201381.","journal-title":"Drugs"},{"issue":"11","key":"1510_CR11","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777\u201389.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1510_CR12","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3802\/jgo.2017.28.e77","volume":"28","author":"J Zhu","year":"2017","unstructured":"Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecologic Oncol. 2017;28(6):e77.","journal-title":"J Gynecologic Oncol"},{"key":"1510_CR13","doi-asserted-by":"crossref","unstructured":"Eymerit-Morin C, Ilenko A, Gaillard T, Varinot J, Comp\u00e9rat E, Bendifallah S et al. PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: a series of 232 cases. Eur J Histochemistry: EJH. 2021;65(1).","DOI":"10.4081\/ejh.2021.3185"},{"issue":"1","key":"1510_CR14","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41598-021-83276-z","volume":"11","author":"SK Parvathareddy","year":"2021","unstructured":"Parvathareddy SK, Siraj AK, Al-Badawi IA, Tulbah A, Al-Dayel F, Al-Kuraya KS. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Sci Rep. 2021;11(1):3750.","journal-title":"Sci Rep"},{"key":"1510_CR15","doi-asserted-by":"crossref","unstructured":"Matsuura H, Miyamoto M, Hada T, Ishibashi H, Iwahashi H, Kakimoto S et al. The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. Arch Gynecol Obstet. 2022.","DOI":"10.1007\/s00404-022-06582-5"},{"issue":"1","key":"1510_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5858\/arpa.2021-0151-CP","volume":"147","author":"JE Willis","year":"2023","unstructured":"Willis JE, Eyerer F, Walk EE, Vasalos P, Bradshaw G, Yohe SL, et al. Companion Diagnostics: lessons learned and the path Forward from the programmed death Ligand-1 Rollout. Arch Pathol Lab Med. 2023;147(1):62\u201370.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"1510_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti\u2013PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147\u201353.","journal-title":"Ann Oncol"},{"key":"1510_CR18","doi-asserted-by":"crossref","unstructured":"Yu W, Shao A, Ren X, Chen Z, Xu J, Wei Q. Comparison of Immune Checkpoint molecules PD-1 and PD-L1 in Paired Primary and recurrent glioma: increasing Trend when recurrence. Brain Sci. 2022;12(2).","DOI":"10.3390\/brainsci12020266"},{"issue":"3","key":"1510_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti\u2013PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245\u201353.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1510_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12935-020-01273-0","volume":"20","author":"M Ye","year":"2020","unstructured":"Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, et al. Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int. 2020;20:186.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1510_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-017-0304-9","volume":"10","author":"M Li","year":"2017","unstructured":"Li M, Li H, Liu F, Bi R, Tu X, Chen L, et al. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res. 2017;10(1):9.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1510_CR22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41598-019-38653-0","volume":"9","author":"M Yano","year":"2019","unstructured":"Yano M, Katoh T, Miyazawa M, Miyazawa M, Ogane N, Miwa M, et al. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Sci Rep. 2019;9(1):2397.","journal-title":"Sci Rep"},{"issue":"2","key":"1510_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/PGP.0000000000000682","volume":"40","author":"SY Lin","year":"2021","unstructured":"Lin SY, Hang JF, Lin YY, Lai CR, Ho HL, Chou TY. Diffuse intratumoral stromal inflammation in Ovarian Clear Cell Carcinoma is Associated with loss of Mismatch repair protein and high PD-L1 expression. Int J Gynecol Pathology: Official J Int Soc Gynecol Pathologists. 2021;40(2):148\u201355.","journal-title":"Int J Gynecol Pathology: Official J Int Soc Gynecol Pathologists"},{"issue":"1","key":"1510_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/PAS.0000000000001975","volume":"47","author":"SY Lin","year":"2023","unstructured":"Lin SY, Hang JF, Lai CR, Chan IS, Shih YC, Jiang LY, et al. Loss of Major Histocompatibility Complex Class I, CD8\u2009+\u2009tumor-infiltrating lymphocytes, and PD-L1 expression in Ovarian Clear Cell Carcinoma. Am J Surg Pathol. 2023;47(1):124\u201330.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1510_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ajcp\/aqad073","volume":"160","author":"R Wilkins","year":"2023","unstructured":"Wilkins R, Lin LH, Xia R, Shiomi T, Zamuco RD, Shukla PS. Clinical outcome and morphology-based analysis of p53 aberrant and Mismatch repair protein-deficient ovarian clear cell Carcinoma and their Association with p16, HER2, and PD-L1 expression. Am J Clin Pathol. 2023;160(5):466\u201376.","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"1510_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/PAS.0000000000001503","volume":"44","author":"H Chen","year":"2020","unstructured":"Chen H, Molberg K, Strickland AL, Castrillon DH, Carrick K, Jiang Q, et al. PD-L1 expression and CD8\u2009+\u2009tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade Serous Carcinoma. Am J Surg Pathol. 2020;44(8):1050\u201360.","journal-title":"Am J Surg Pathol"},{"key":"1510_CR27","volume-title":"Female genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020","unstructured":"WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon, France: International Agency for Research on Cancer; 2020."},{"issue":"2","key":"1510_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1510_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines\u00ae insights: ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972\u201380.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1510_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53(2):141\u201356.","journal-title":"Pathology"},{"issue":"7","key":"1510_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080\u20137.","journal-title":"Ann Oncol"},{"issue":"12","key":"1510_CR32","first-page":"835","volume":"52","author":"MJ Li","year":"2017","unstructured":"Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, et al. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2017;52(12):835\u201343.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"7","key":"1510_CR33","doi-asserted-by":"publisher","first-page":"100159","DOI":"10.1016\/j.modpat.2023.100159","volume":"36","author":"AI Fernandez","year":"2023","unstructured":"Fernandez AI, Gaule P, Rimm DL. Tissue age affects antigenicity and scoring for the 22C3 immunohistochemistry Companion Diagnostic Test. Mod Pathol. 2023;36(7):100159.","journal-title":"Mod Pathol"},{"issue":"24","key":"1510_CR34","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline diagnosis and after Chemotherapy. Clin Cancer Res. 2020;26(24):6453\u201363.","journal-title":"Clin Cancer Res"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-024-01510-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:02:18Z","timestamp":1718449338000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-024-01510-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1186\/s13000-024-01510-4","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Peking Union Hospital (I-22PJ1120).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}